Source: Virtual Congress 2021 – COVID - 19 biomarkers



Rating:

Share or cite this content

Citations should be made in the following way:
S. Sutharsan (Essen, Germany), M. Berger (Essen, Germany), J. Andrä (Essen, Germany), L. Jehn (Essen, Germany), C. Taube (Essen, Germany), T. Brenner (Essen, Germany), S. Kattner (Essen, Germany), A. Limmer (Essen, Germany), F. Bonella (Essen, Germany). Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection. 655

Member's Comments

No comment yet.

Related content which might interest you: Serum CC16 is a potential predictor for IPF diagnosis and prognosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Serum biomarkers in SSc-ILD: association with presence, severity and prognosis Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Circulating fetuin-A as a biomarker predicting mortality in ICU septic patients Source: International Congress 2017 – Sepsis, infections, ARDS and beyond Year: 2017 Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis Source: Eur Respir J , 49 (2) 1501924; DOI: 10.1183/13993003.01924-2015 Year: 2017 Procalcitonin and C-reactive protein levels correlate worse with organ failure than NT-proBNP levels in septic patients Source: Eur Respir J 2006; 28: Suppl. 50, 61s Year: 2006 Could KL-6 levels in COVID-19 help to predict lung disease ? Source: Virtual Congress 2021 – COVID - 19: lessons learned Year: 2021 Circulating total leptin as a diagnostic and prognostic biomarker in sepsis Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure Year: 2019 Admission serum glucose levels are a risk factor predicting short- and long-term mortality in community acquired pneumonia Source: Annual Congress 2012 - Hot topics in respiratory infections Year: 2012 Mortality risk prediction in COPD by a prognostic biomarker panel Source: Eur Respir J 2014; 44: 1557-1570 Year: 2014 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Plasma BNP levels as a biomarker of hemodynamic outcome and mortality in cteph following pea Source: Annual Congress 2009 - Acute and chronic venous thromboembolic disease Year: 2009 The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017 The serum YKL-40 is a useful biomarker for asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Does the serum C-reactive protein (CRP) predict adverse outcomes in patients admitted with community acquired pneumonia? Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Stability of serum biomarkers and their associations with clinical outcomes in COPD patients and controls: a longitudinal study Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 High level of serum SP-D with normal range of KL-6 predicts a good prognosis of patients with fibrotic changes on HRCT Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study. Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 Increased serum IL-17 does not predict future risk and impairment in asthma Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches Year: 2009